Medicxi launches €267m fund

Novartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept.

Read more

Germany is blocking EU Unitary Patent Court

Germany’s Constitutional Court has stopped the government from ratifying the EU’s Unitary Patent Package. At the time of the announcement, The German Bundestag and Council of Federal states had already adopted and signed the legislation.

Read more

Recipharm: Strategic appointment

Contract development and manufacturing organisation Recipharm has appointed Shabbir Mostafa as Director, Business Management UK & Ireland. He will be responsible for supporting customers in the UK and Ireland and driving sales of Recipharm’s manufacturing services.
Read more

Abivax Ebola antiviral gets financing

French virology company Abivac will receive €390,000 for the development of a polyclonal antibody cocktail to fight Ebola.

Read more

LowCross-Buffer

Antibody and sample diluent for minimizing nonspecific binding, cross-reactivities and matrix effects in immunoassays.

Read more

Centogene raises a €25m in Series A financing

Orphan diseases diagnostics specialist Centogene AG said it will use the funds for biomarker and CDx development based on its proprietary CentoMD mutation database.

Read more

Virbac: Managing global operations

French vet-med maker Virbac has named Frédéric Jodogne as Corporate Industrial Operations director in early April. He is in charge of implementing, organizing and leading supply chain and industrial strategies of the Group. 
Read more

Bonesupport is planning €60m IPO

Swedish orthobiologics company Bonesupport Holding AB announced on Sunday it will go public at Nasdaq Stockholm.

Read more

Targovax raises €21m in private placement

Norwegian cancer med developer Targovax ASA has doubled its cash and cash equivalents as of 31 December 2016 by raising NOK200m (€21m) in a private placement of new shares.

Read more

Luminary in vaccine research

Jan Holmgren, developer of the first effective oral cholera vaccine, has been awarded the 2017 Sabin Gold Medal for his pioneering contributions to oral vaccine research and mucosal immunology, and his leadership in the discovery of the world’s first effective oral cholera vaccine.
Read more